Panelists discuss where and when sequencing axatilimab becomes appropriate within the clinical setting, as well as safety precautions associated with the drug.
Shernan Holtan, MD
Articles by Shernan Holtan, MD
Panelists discuss what the AGAVE-201 study displayed.
Panelists give an overview of chronic graft-vs-host disease, its history of treatment, how it is handled in the modern day, and the study design of AGAVE-201.
Panelists give an overview of Graft-vs-host Disease and the modern landscape of treatment.